1921
Volume 103, Issue 3
  • ISSN: 0002-9637
  • E-ISSN: 1476-1645

Abstract

Abstract.

Mass azithromycin distribution has been shown to reduce all-cause mortality in preschool children in sub-Saharan Africa. However, substantial heterogeneity in the apparent effect has been noted across geographic settings, suggesting a greater relative benefit in higher mortality settings. Here, we evaluated the relationship between the underlying mortality rate and the efficacy of azithromycin for the prevention of child mortality using data from multiple sites in Ethiopia, Malawi, Niger, and Tanzania. Between regions, we find no strong evidence of effect modification of the efficacy of azithromycin distribution for the prevention of child mortality by the underlying mortality rate ( = 0.12), although a modest effect is consistent with our findings. Higher mortality settings could be prioritized, however, because of the larger number of deaths which could be averted with azithromycin distribution.

[open-access] This is an open-access article distributed under the terms of the Creative Commons Attribution (CC-BY) License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Loading

Article metrics loading...

The graphs shown below represent data from March 2017
/content/journals/10.4269/ajtmh.18-1003
2019-02-07
2020-11-25
Loading full text...

Full text loading...

/deliver/fulltext/14761645/103/3/tpmd181003.html?itemId=/content/journals/10.4269/ajtmh.18-1003&mimeType=html&fmt=ahah

References

  1. Porco TC et al., 2009. Effect of mass distribution of azithromycin for trachoma control on overall mortality in Ethiopian children: a randomized trial. JAMA 302: 962968.
    [Google Scholar]
  2. O’Brien KS et al., 2018. Childhood mortality after mass distribution of azithromycin: a secondary analysis of the PRET cluster-randomized trial in Niger. Pediatr Infect Dis J 37: 10821086.
    [Google Scholar]
  3. Keenan JD, Ayele B, Gebre T, Zerihun M, Zhou Z, House JI, Gaynor BD, Porco TC, Emerson PM, Lietman TM, 2011. Childhood mortality in a cohort treated with mass azithromycin for trachoma. Clin Infect Dis 52: 883888.
    [Google Scholar]
  4. Keenan JD et al., 2018. Azithromycin to reduce childhood mortality in sub-Saharan Africa. New Engl J Med 378: 15831592.
    [Google Scholar]
  5. O’Brien KS, Emerson P, Hooper PJ, Reingold AL, Dennis EG, Keenan JD, Lietman TM, Oldenburg CE, 2019. Antimicrobial resistance following mass azithromycin distribution for trachoma: a systematic review. Lancet Infect Dis 19: e14e25.
    [Google Scholar]
  6. Bloch EM, West SK, Mabula K, Weaver J, Mrango Z, Muñoz B, Lietman T, Coles C, 2017. Antibiotic resistance in young children in Kilosa District, Tanzania 4 years after mass distribution of azithromycin for trachoma control. Am J Trop Med Hyg 97: 815818.
    [Google Scholar]
  7. Seidman JC, Johnson LB, Levens J, Mkocha H, Muñoz B, Silbergeld EK, West SK, Coles CL, 2016. Longitudinal comparison of antibiotic resistance in diarrheagenic and non-pathogenic Escherichia coli from young Tanzanian children. Front microbiol 7: 1420.
    [Google Scholar]
  8. Skalet AH et al., 2010. Antibiotic selection pressure and macrolide resistance in nasopharyngeal Streptococcus pneumoniae: a cluster-randomized clinical trial. PLoS Med 7: e1000377.
    [Google Scholar]
  9. Oldenburg CE et al., 2020. Mass azithromycin distribution to prevent childhood mortality: a pooled analysis of cluster randomized trials. Am J Trop Med Hyg 100: 691695.
    [Google Scholar]
  10. Amza A et al., 2017. A cluster-randomized trial to assess the efficacy of targeting trachoma treatment to children. Clin Infect Dis 64: 743750.
    [Google Scholar]
  11. Oldenburg CE et al., 2018. Comparison of mass azithromycin coverage targets of children in Niger: a cluster-randomized trachoma trial. Am J Trop Med Hyg 98: 389395.
    [Google Scholar]
  12. Amza A et al., 2018. Effectiveness of expanding annual mass azithromycin distribution treatment coverage for trachoma in Niger: a cluster randomised trial. Br J Ophthalmol 102: 680686.
    [Google Scholar]
  13. Rothman KJ, Greenland S, 2012. Modern Epidemiology, 3rd edition. Philadelphia, PA: LWW.
    [Google Scholar]
  14. Oron AP et al., 2020. Effect modification by baseline mortality in the MORDOR azithromycin trial. Am J Trop Med Hyg 103: 12951300.
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journals/10.4269/ajtmh.18-1003
Loading
/content/journals/10.4269/ajtmh.18-1003
Loading

Data & Media loading...

  • Received : 25 Dec 2018
  • Accepted : 23 Jan 2019
  • Published online : 07 Feb 2019
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error